The global tumor ablation market revenue was around US$ 1.3 billion in 2022 and is estimated to reach US$ 4.09 billion by 2031, growing at a compound annual growth rate (CAGR) of 13.6% during the forecast period from 2023 to 2031.
Tumor ablation is a minimally invasive procedure that is frequently used to treat tumors of the bone, liver, kidney, and lung. Thermal energy is utilized to cool or heat tissue to cytotoxic levels in the tumor ablation process. Less than -40 degrees Celsius or greater than 60 degrees Celsius are the temperatures employed to thermally destruct the tumor cells.
Market Driving Factors
Regional Analysis
North America dominated the market in terms of the largest share. This is due to the government support for high purchasing power parity, high-quality healthcare, the availability of reimbursements, and rising rates of cancer are some of the main drivers of this region's growth. For example, the Patient Protection and Affordable Care Act (PPACA) in the United States encourages quality and accessibility of healthcare by lowering the cost of healthcare for both individuals and the government through the use of health coverage policies. Additionally, the precision medicine project develops individualized therapies based on distinct illness characteristics. Therefore, it is projected that such government actions will enhance the whole healthcare system. Thus, these factors increase market growth.
Segmentation Insights
Treatment Insights
The percutaneous ablation segment is anticipated to dominate the market during the projection period. This is due to faster healing, little scarring, and better safety. Additionally, it is projected that features such as a short recovery period after surgery, and patient comfort will further increase segment demand. Thus, these factors will propel the market growth in this segment.
Application Insights
Liver cancer dominated the market in terms of the highest CAGR during the forecast period. This is explained by the increasing prevalence of primary liver cancer and bile duct cancer. Furthermore, it is projected that the availability of cutting-edge techniques and rising cancer prevalence will promote market expansion in this segment.
Technology Insights
The radiofrequency ablation segment dominated the market in terms of the largest revenue. This is due to the Its advantages, such as specificity and effectiveness in solid tumor ablation treatments in the liver and kidney. Additionally, this segment is utilized to treat numerous tumors simultaneously. Furthermore, many electrodes can be positioned at various places, increasing procedural efficiency. This is anticipated to increase the rate of advanced tumor ablation technology adoption.
The Microwave Ablation segment is anticipated to dominate the market growth. This is due to the use of this segment in tissues like bones and lungs that have poor electrical conductivity. Furthermore, larger tumor ablation volumes, less pain during ablation, consistently high temperatures and effective heating of the cystic mass are some of this technology's major advantages. It is believed that these advantages would help this segment flourish. Additionally, limited operation time (5–10 minutes), improved efficacy with few problems, and shorter hospital stays are expected to fuel the market growth.
Prominent Companies
Segmentation Outline
The global tumor ablation market segmentation focuses on Treatment, Application, Technology, and Region.
By Treatment
By Application
By Technology
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL TUMOR ABLATION MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: TUMOR ABLATION MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL TUMOR ABLATION MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT
5.1 OVERVIEW
5.2 SURGICAL ABLATION
5.3 LAPAROSCOPIC ABLATION
5.4 PERCUTANEOUS ABLATION
6 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 KIDNEY CANCER
6.3 LIVER CANCER
6.4 BREAST CANCER
6.5 LUNG CANCER
6.6 PROSTATE CANCER
7 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 RADIOFREQUENCY ABLATION
7.3 MICROWAVE ABLATION
7.4 CRYOABLATION
7.5 IRREVERSIBLE ELECTROPORATION ABLATION
7.6 OTHER ABLATION TECHNOLOGIES
8 GLOBAL TUMOR ABLATION MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL TUMOR ABLATION MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 HEALTH TRONICS INC
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ETHICON
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 MISONIX INC
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 SMITH+ NEPHEW
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 INTEGRA LIFE SCIENCES
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 BOSTON SCIENTIFIC CORPORATION
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 MEDTRONIC INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 JOHNSON AND JOHNSON
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 GALIL MEDICAL INC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 ANGIODYNAMICS
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved